VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q50419498 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000212.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q50419498‏
024 ‎‡a 0000-0002-5663-282X‏ ‎‡2 orcid‏
024 ‎‡a 35515844300‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q50419498‏
100 0 ‎‡a Carolyn J. Anderson‏ ‎‡c American cardiologist‏ ‎‡9 en‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Carolyn J Anderson‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.‏
670 ‎‡a Author's 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.‏
670 ‎‡a Author's (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity‏
670 ‎‡a Author's ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer‏
670 ‎‡a Author's 64Cu-labeled somatostatin analogues conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studies‏
670 ‎‡a Author's A new phosphonate pendant-armed cross-bridged tetraamine chelator accelerates copper(ii) binding for radiopharmaceutical applications‏
670 ‎‡a Author's Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor‏
670 ‎‡a Author's Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis‏
670 ‎‡a Author's Characterization and evaluation of‏
670 ‎‡a Author's Characterization and evaluation of (64)Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ 6‏
670 ‎‡a Author's Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells.‏
670 ‎‡a Author's Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals‏
670 ‎‡a Author's Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications.‏
670 ‎‡a Author's Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model‏
670 ‎‡a Author's Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.‏
670 ‎‡a Author's Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats‏
670 ‎‡a Author's Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice‏
670 ‎‡a Author's Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.‏
670 ‎‡a Author's Comparison of Four Bifunctional Chelates for Radiolabeling Monoclonal Antibodies with Copper Radioisotopes: Biodistribution and Metabolism‏
670 ‎‡a Author's Components of a curriculum for molecular imaging scientists‏
670 ‎‡a Author's Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3.‏
670 ‎‡a Author's Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease‏
670 ‎‡a Author's Copper-64 Radiopharmaceuticals for Oncologic Imaging‏
670 ‎‡a Author's Copper chelation chemistry and its role in copper radiopharmaceuticals.‏
670 ‎‡a Author's Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines‏
670 ‎‡a Author's Cu(I)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides.‏
670 ‎‡a Author's Current status and future challenges for molecular imaging‏
670 ‎‡a Author's Design of targeted cardiovascular molecular imaging probes‏
670 ‎‡a Author's DOTA-D-Tyr‏
670 ‎‡a Author's DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.‏
670 ‎‡a Author's Efficient production of high specific activity 64Cu using a biomedical cyclotron‏
670 ‎‡a Author's Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide‏
670 ‎‡a Author's Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma‏
670 ‎‡a Author's Evaluation of a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody‏
670 ‎‡a Author's Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.‏
670 ‎‡a Author's Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging‏
670 ‎‡a Author's Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents‏
670 ‎‡a Author's Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents‏
670 ‎‡a Author's Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model‏
670 ‎‡a Author's Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs‏
670 ‎‡a Author's High purity production and potential applications of copper-60 and copper-61‏
670 ‎‡a Author's Highly-efficient and versatile fluorous-tagged Cu(I)-catalyzed azide-alkyne cycloaddition ligand for preparing bioconjugates.‏
670 ‎‡a Author's Homodimeric and heterodimeric bis‏
670 ‎‡a Author's Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones‏
670 ‎‡a Author's <i>ALDH1A1</i> Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper‏
670 ‎‡a Author's Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide‏
670 ‎‡a Author's Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.‏
670 ‎‡a Author's Imaging the Tumor Microenvironment.‏
670 ‎‡a Author's In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer‏
670 ‎‡a Author's In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.‏
670 ‎‡a Author's In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake‏
670 ‎‡a Author's In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models‏
670 ‎‡a Author's In vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands.‏
670 ‎‡a Author's In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands.‏
670 ‎‡a Author's In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver.‏
670 ‎‡a Author's Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.‏
670 ‎‡a Author's Investigation of copper-azamacrocyclic complexes by high-performance liquid chromatography‏
670 ‎‡a Author's Liposomal Cu-64 labeling method using bifunctional chelators: poly‏
670 ‎‡a Author's Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects.‏
670 ‎‡a Author's Macrocyclic diamide ligand systems: potential chelators for 64Cu- and 68Ga-based positron emission tomography imaging agents‏
670 ‎‡a Author's Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy‏
670 ‎‡a Author's N,N'-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies‏
670 ‎‡a Author's Nanogels from metal-chelating crosslinkers as versatile platforms applied to copper-64 PET imaging of tumors and metastases‏
670 ‎‡a Author's New Bifunctional Chelator p-SCN-PhPr-NE3TA for Copper-64: Synthesis, Peptidomimetic Conjugation, Radiolabeling, and Evaluation for PET Imaging.‏
670 ‎‡a Author's New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides‏
670 ‎‡a Author's New hydroxybenzyl and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium‏
670 ‎‡a Author's New hydroxybenzyl and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium(III) and indium(III)‏
670 ‎‡a Author's Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line.‏
670 ‎‡a Author's PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.‏
670 ‎‡a Author's Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells‏
670 ‎‡a Author's Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403‏
670 ‎‡a Author's Preclinical Evaluation of 18F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors‏
670 ‎‡a Author's Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.‏
670 ‎‡a Author's Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator‏
670 ‎‡a Author's Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors‏
670 ‎‡a Author's Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator‏
670 ‎‡a Author's Progestin radiopharmaceuticals labeled with technetium and rhenium: synthesis, binding affinity, and in vivo distribution of a new progestin N2S2-metal conjugate‏
670 ‎‡a Author's Quantification of regional myocardial perfusion with generator-produced 62Cu-PTSM and positron emission tomography.‏
670 ‎‡a Author's Radioactivity-synchronized fluorescence enhancement using a radionuclide fluorescence-quenched dye.‏
670 ‎‡a Author's Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.‏
670 ‎‡a Author's Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.‏
670 ‎‡a Author's Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64‏
670 ‎‡a Author's Radiometal-labeled agents‏
670 ‎‡a Author's Radiometal-labeled agents (non-technetium) for diagnostic imaging‏
670 ‎‡a Author's Rapid and sensitive LC-MS approach to quantify non-radioactive transition metal impurities in metal radionuclides‏
670 ‎‡a Author's Reactivity of p-[18F]fluorophenacyl bromide for radiolabeling of proteins and peptides‏
670 ‎‡a Author's Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.‏
670 ‎‡a Author's Roles of Atox1 and p53 in the trafficking of copper-64 to tumor cell nuclei: implications for cancer therapy‏
670 ‎‡a Author's Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide‏
670 ‎‡a Author's Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes.‏
670 ‎‡a Author's Synthesis and preliminary evaluation of an ¹⁸F-labeled oleic acid analog for PET imaging of fatty acid uptake and metabolism‏
670 ‎‡a Author's Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer‏
670 ‎‡a Author's Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases‏
670 ‎‡a Author's The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.‏
670 ‎‡a Author's The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow‏
670 ‎‡a Author's The in vivo behavior of copper-64-labeled azamacrocyclic complexes‏
670 ‎‡a Author's The role of p53 in the trafficking of copper-64 to tumor cell nuclei.‏
670 ‎‡a Author's Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model.‏
670 ‎‡a Author's Toxicity and dosimetry of‏
670 ‎‡a Author's Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.‏
670 ‎‡a Author's Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma‏
670 ‎‡a Author's Visualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.‏
670 ‎‡a Author's Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown‏
909 ‎‡a (scopus) 35515844300‏ ‎‡9 1‏
909 ‎‡a (orcid) 000000025663282x‏ ‎‡9 1‏
919 ‎‡a invivobehaviorofcopper64labeledazamacrocycliccomplexes‏ ‎‡A The in vivo behavior of copper-64-labeled azamacrocyclic complexes‏ ‎‡9 1‏
919 ‎‡a chemokinereceptorscxcr4cxcr7andtheirprimaryheterodimericligandscxcl12andcxcl12highmobilitygroupbox1inpancreaticcancergrowthanddevelopmentfindingflow‏ ‎‡A The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow‏ ‎‡9 1‏
919 ‎‡a biodistributionofgdlabeledmagneticresonancecontrastagentsinatransgenicmousemodelofrenalfailurediffersgreatlyfromcontrolmice‏ ‎‡A The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.‏ ‎‡9 1‏
919 ‎‡a targetingthealphavbeta3integrinforsmallanimalpetctofosteolyticbonemetastases‏ ‎‡A Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases‏ ‎‡9 1‏
919 ‎‡a targetingpsmawithacu64labeledphosphoramidateinhibitorforpetctimagingofvariantpsmaexpressingxenograftsinmousemodelsofprostatecancer‏ ‎‡A Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer‏ ‎‡9 1‏
919 ‎‡a synthesisandpreliminaryevaluationofan18flabeledoleicacidanalogforpetimagingoffattyaciduptakeandmetabolism‏ ‎‡A Synthesis and preliminary evaluation of an ¹⁸F-labeled oleic acid analog for PET imaging of fatty acid uptake and metabolism‏ ‎‡9 1‏
919 ‎‡a synthesisandcharacterizationofthecopper2complexesofnewn2s2donormacrocyclicligandssynthesisandinvivoevaluationofthe64cucomplexes‏ ‎‡A Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes.‏ ‎‡9 1‏
919 ‎‡a synthesisandbiologicalevaluationoftc99mcyclopentadienyltricarbonyltechnetiumlabeledoctreotide‏ ‎‡A Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide‏ ‎‡9 1‏
919 ‎‡a rolesofatox1andp53inthetraffickingofcopper64totumorcellnucleiimplicationsforcancertherapy‏ ‎‡A Roles of Atox1 and p53 in the trafficking of copper-64 to tumor cell nuclei: implications for cancer therapy‏ ‎‡9 1‏
919 ‎‡a receptorbindingbiodistributionandmetabolismstudiesof64cudotacetuximabapetimagingagentforepidermalgrowthfactorreceptorpositivetumors‏ ‎‡A Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.‏ ‎‡9 1‏
919 ‎‡a reactivityofpfluorophenacylbromideforradiolabelingofproteinsandpeptides‏ ‎‡A Reactivity of p-[18F]fluorophenacyl bromide for radiolabeling of proteins and peptides‏ ‎‡9 1‏
919 ‎‡a rapidandsensitivelcmsapproachtoquantifynonradioactivetransitionmetalimpuritiesinmetalradionuclides‏ ‎‡A Rapid and sensitive LC-MS approach to quantify non-radioactive transition metal impurities in metal radionuclides‏ ‎‡9 1‏
919 ‎‡a radiometallabeledagentsnontechnetiumfordiagnosticimaging‏ ‎‡A Radiometal-labeled agents (non-technetium) for diagnostic imaging‏ ‎‡9 1‏
919 ‎‡a radiometallabeledagents‏ ‎‡A Radiometal-labeled agents‏ ‎‡9 1‏
919 ‎‡a radiolabelingoftetaandcbte2aconjugatedpeptideswithcopper64‏ ‎‡A Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64‏ ‎‡9 1‏
919 ‎‡a radiolabelingandinvivobehaviorofcopper64labeledcrossbridgedcyclamligands‏ ‎‡A Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.‏ ‎‡9 1‏
919 ‎‡a radioimmunotherapywitha64culabeledmonoclonalantibodyacomparisonwith67cu‏ ‎‡A Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.‏ ‎‡9 1‏
919 ‎‡a radioactivitysynchronizedfluorescenceenhancementusingaradionuclidefluorescencequencheddye‏ ‎‡A Radioactivity-synchronized fluorescence enhancement using a radionuclide fluorescence-quenched dye.‏ ‎‡9 1‏
919 ‎‡a quantificationofregionalmyocardialperfusionwithgeneratorproduced62cuptsmandpositronemissiontomography‏ ‎‡A Quantification of regional myocardial perfusion with generator-produced 62Cu-PTSM and positron emission tomography.‏ ‎‡9 1‏
919 ‎‡a progestinradiopharmaceuticalslabeledwithtechnetiumandrheniumsynthesisbindingaffinityandinvivodistributionofanewprogestinn2s2metalconjugate‏ ‎‡A Progestin radiopharmaceuticals labeled with technetium and rhenium: synthesis, binding affinity, and in vivo distribution of a new progestin N2S2-metal conjugate‏ ‎‡9 1‏
919 ‎‡a preparationandbiologicalevaluationofcopper64labeledtyr3octreotateusingacrossbridgedmacrocyclicchelator‏ ‎‡A Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator‏ ‎‡9 1‏
919 ‎‡a preparationandbiologicalevaluationof64cucbte2asst2antasomatostatinantagonistforpetimagingofsomatostatinreceptorpositivetumors‏ ‎‡A Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors‏ ‎‡9 1‏
919 ‎‡a preparationandbiologicalevaluationof64culabeledtyr3octreotateusingaphosphonicacidbasedcrossbridgedmacrocyclicchelator‏ ‎‡A Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator‏ ‎‡9 1‏
919 ‎‡a preclinicalimmunopetctimagingusingzr89labeledantipdl1monoclonalantibodyforassessingradiationinducedpdl1upregulationinheadandneckcancerandmelanoma‏ ‎‡A Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.‏ ‎‡9 1‏
919 ‎‡a preclinicalevaluationof18f105010todeterminetimingofapoptoticresponsetochemotherapyinsolidtumors‏ ‎‡A Preclinical Evaluation of 18F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors‏ ‎‡9 1‏
919 ‎‡a preclinicaldosimetryimagingandtargetedradionuclidetherapystudiesoflu177labeledalbuminbindingpsmatargetedct‏ ‎‡A Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403‏ ‎‡9 1‏
919 ‎‡a positronemissiontomographyimagingofmacaqueswithtuberculosisidentifiestemporalchangesingranulomaglucosemetabolismandintegrinα4β1expressingimmunecells‏ ‎‡A Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells‏ ‎‡9 1‏
919 ‎‡a petimagingofverylateantigen4inmelanomacomparisonof68gaand64culabelednodagaandcbte1a1pllp2aconjugates‏ ‎‡A PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.‏ ‎‡9 1‏
919 ‎‡a nuclearuptakeanddosimetryof64culabeledchelatorsomatostatinconjugatesinansstr2transfectedhumantumorcellline‏ ‎‡A Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line.‏ ‎‡9 1‏
919 ‎‡a newhydroxybenzylandhydroxypyridylmethylsubstitutedtriazacyclononaneligandsforusewithgallium3andindium3‏ ‎‡A New hydroxybenzyl and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium(III) and indium(III)‏ ‎‡9 1‏
919 ‎‡a newhydroxybenzylandhydroxypyridylmethylsubstitutedtriazacyclononaneligandsforusewithgallium‏ ‎‡A New hydroxybenzyl and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium‏ ‎‡9 1‏
919 ‎‡a newcrossbridgedcyclamderivativecbte1k1panimprovedbifunctionalchelatorforcopperradionuclides‏ ‎‡A New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides‏ ‎‡9 1‏
919 ‎‡a newbifunctionalchelatorpscnphprne3taforcopper64synthesispeptidomimeticconjugationradiolabelingandevaluationforpetimaging‏ ‎‡A New Bifunctional Chelator p-SCN-PhPr-NE3TA for Copper-64: Synthesis, Peptidomimetic Conjugation, Radiolabeling, and Evaluation for PET Imaging.‏ ‎‡9 1‏
919 ‎‡a nanogelsfrommetalchelatingcrosslinkersasversatileplatformsappliedtocopper64petimagingoftumorsandmetastases‏ ‎‡A Nanogels from metal-chelating crosslinkers as versatile platforms applied to copper-64 PET imaging of tumors and metastases‏ ‎‡9 1‏
919 ‎‡a nnethylene50150cysteineeccomplexesofga3andin3molecularmodelingthermodynamicstabilityandinvivostudies‏ ‎‡A N,N'-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies‏ ‎‡9 1‏
919 ‎‡a monoclonalantibodiesforcopper64petdosimetryandradioimmunotherapy‏ ‎‡A Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy‏ ‎‡9 1‏
919 ‎‡a macrocyclicdiamideligandsystemspotentialchelatorsfor64cuand68gabasedpositronemissiontomographyimagingagents‏ ‎‡A Macrocyclic diamide ligand systems: potential chelators for 64Cu- and 68Ga-based positron emission tomography imaging agents‏ ‎‡9 1‏
919 ‎‡a liposomalcu64labelingmethodusingbifunctionalchelatorspolyethyleneglycolspacerandchelatoreffects‏ ‎‡A Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects.‏ ‎‡9 1‏
919 ‎‡a liposomalcu64labelingmethodusingbifunctionalchelatorspoly‏ ‎‡A Liposomal Cu-64 labeling method using bifunctional chelators: poly‏ ‎‡9 1‏
919 ‎‡a investigationofcopperazamacrocycliccomplexesbyhighperformanceliquidchromatography‏ ‎‡A Investigation of copper-azamacrocyclic complexes by high-performance liquid chromatography‏ ‎‡9 1‏
919 ‎‡a integrinα5β3asapetimagingbiomarkerforosteoclastnumberinmousemodelsofnegativeandpositiveosteoclastregulation‏ ‎‡A Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.‏ ‎‡9 1‏
919 ‎‡a invivotranschelationofcopper64fromtetaoctreotidetosuperoxidedismutaseinratliver‏ ‎‡A In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver.‏ ‎‡9 1‏
919 ‎‡a invivoevaluationofcopper64labeledmonooxotetraazamacrocyclicligands‏ ‎‡A In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands.‏ ‎‡9 1‏
919 ‎‡a invivobehaviorofcopper64labeledmethanephosphonatetetraazamacrocyclicligands‏ ‎‡A In vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands.‏ ‎‡9 1‏
919 ‎‡a invitroandinvivoinvestigationofmatrixmetalloproteinaseexpressioninmetastatictumormodels‏ ‎‡A In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models‏ ‎‡9 1‏
919 ‎‡a invitroandinvivoevaluationof64cutetatyr3octreotateanewsomatostatinanalogwithimprovedtargettissueuptake‏ ‎‡A In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake‏ ‎‡9 1‏
919 ‎‡a invitroandinvivoevaluationof64curadiolabeledkccyslpeptidesfortargetingepidermalgrowthfactorreceptor2inbreastcarcinomas‏ ‎‡A In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.‏ ‎‡9 1‏
919 ‎‡a invitroandinvivoevaluationof64culabeledsararbombesinanalogsingastrinreleasingpeptidereceptorexpressingprostatecancer‏ ‎‡A In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer‏ ‎‡9 1‏
919 ‎‡a imagingthetumormicroenvironment‏ ‎‡A Imaging the Tumor Microenvironment.‏ ‎‡9 1‏
919 ‎‡a imagingofegfrandegfrtyrosinekinaseoverexpressionintumorsbynuclearmedicinemodalities‏ ‎‡A Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.‏ ‎‡9 1‏
919 ‎‡a identificationofthesolubleinvivometabolitesofindium111diethylenetriaminepentaaceticacid500phe1octreotide‏ ‎‡A Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide‏ ‎‡9 1‏
919 ‎‡a aldh1a11geneexpressionandcellularcopperlevelsbetweenlowandhighlymetastaticosteosarcomaprovideacasefornovelrepurposingwithdisulfiramandcopper‏ ‎‡A <i>ALDH1A1</i> Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper‏ ‎‡9 1‏
919 ‎‡a homodimericandheterodimericbisaminothioloxometalcomplexeswithrhenium5andtechnetium5controlofheterodimericcomplexformationandanapproachtometalcomplexesthatmimicsteroidhormones‏ ‎‡A Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones‏ ‎‡9 1‏
919 ‎‡a homodimericandheterodimericbis‏ ‎‡A Homodimeric and heterodimeric bis‏ ‎‡9 1‏
919 ‎‡a highlyefficientandversatilefluoroustaggedcu1catalyzedazidealkynecycloadditionligandforpreparingbioconjugates‏ ‎‡A Highly-efficient and versatile fluorous-tagged Cu(I)-catalyzed azide-alkyne cycloaddition ligand for preparing bioconjugates.‏ ‎‡9 1‏
919 ‎‡a highpurityproductionandpotentialapplicationsofcopper60andcopper61‏ ‎‡A High purity production and potential applications of copper-60 and copper-61‏ ‎‡9 1‏
919 ‎‡a generallyapplicableconvenientsolidphasesynthesisandreceptoraffinitiesofoctreotideanalogs‏ ‎‡A Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs‏ ‎‡9 1‏
919 ‎‡a folatereceptortargetedmultimodalityimagingofovariancancerinanovelsyngeneicmousemodel‏ ‎‡A Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model‏ ‎‡9 1‏
919 ‎‡a exvivoandinvivoevaluationofoverexpressedvla4inmultiplemyelomausingllp2aimagingagents‏ ‎‡A Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents‏ ‎‡9 1‏
919 ‎‡a verylateantigen4α4β1integrintargetedpetimagingofmultiplemyeloma‏ ‎‡A Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma‏ ‎‡9 1‏
919 ‎‡a visualizationandquantificationofsimianimmunodeficiencyvirusinfectedcellsusingnoninvasivemolecularimaging‏ ‎‡A Visualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.‏ ‎‡9 1‏
919 ‎‡a withaferinainhibitsinvivogrowthofbreastcancercellsacceleratedbynotch2knockdown‏ ‎‡A Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown‏ ‎‡9 1‏
919 ‎‡a evaluationofradiolabeledtype4collagenfragmentsaspotentialtumorimagingagents‏ ‎‡A Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents‏ ‎‡9 1‏
919 ‎‡a evaluationofcopperlabeledbifunctionalchelatealbuminconjugatesforbloodpoolimaging‏ ‎‡A Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging‏ ‎‡9 1‏
919 ‎‡a evaluationofcopper64labeledsomatostatinagonistsandantagonistinsstr2transfectedcelllinesthatarepositiveandnegativeforp53implicationsforcancertherapy‏ ‎‡A Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.‏ ‎‡9 1‏
919 ‎‡a evaluationofadirectmethodfortechnetiumlabelingintactandfab21a3ananticolorectalmonoclonalantibody‏ ‎‡A Evaluation of a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody‏ ‎‡9 1‏
919 ‎‡a evaluationof68gaand177ludotapeg4llp2aforvla4targetedpetimagingandtreatmentofmetastaticmelanoma‏ ‎‡A Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma‏ ‎‡9 1‏
919 ‎‡a evaluationofcudotaandcucbte2achelatesfortargetedpositronemissiontomographywithanalphavbeta6specificpeptide‏ ‎‡A Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide‏ ‎‡9 1‏
919 ‎‡a efficientproductionofhighspecificactivity64cuusingabiomedicalcyclotron‏ ‎‡A Efficient production of high specific activity 64Cu using a biomedical cyclotron‏ ‎‡9 1‏
919 ‎‡a dota500tyr1octreotateasomatostatinanalogueforlabelingwithmetalandhalogenradionuclidesforcancerimagingandtherapy‏ ‎‡A DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.‏ ‎‡9 1‏
919 ‎‡a dota500tyr‏ ‎‡A DOTA-D-Tyr‏ ‎‡9 1‏
919 ‎‡a designoftargetedcardiovascularmolecularimagingprobes‏ ‎‡A Design of targeted cardiovascular molecular imaging probes‏ ‎‡9 1‏
919 ‎‡a currentstatusandfuturechallengesformolecularimaging‏ ‎‡A Current status and future challenges for molecular imaging‏ ‎‡9 1‏
919 ‎‡a cu1assistedclickchemistrystrategyforconjugationofnonprotectedcrossbridgedmacrocyclicchelatorstotumourtargetingpeptides‏ ‎‡A Cu(I)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides.‏ ‎‡9 1‏
919 ‎‡a correlatingegfrexpressionwithreceptorbindingpropertiesandinternalizationof64cudotacetuximabin5cervicalcancercelllines‏ ‎‡A Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines‏ ‎‡9 1‏
919 ‎‡a copperchelationchemistryanditsroleincopperradiopharmaceuticals‏ ‎‡A Copper chelation chemistry and its role in copper radiopharmaceuticals.‏ ‎‡9 1‏
919 ‎‡a copper64radiopharmaceuticalsforoncologicimaging‏ ‎‡A Copper-64 Radiopharmaceuticals for Oncologic Imaging‏ ‎‡9 1‏
919 ‎‡a coordinatingradiometalsofcoppergalliumindiumyttriumandzirconiumforpetandspectimagingofdisease‏ ‎‡A Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease‏ ‎‡9 1‏
919 ‎‡a conjugationofmonoclonalantibodieswithtetausingactivatedestersbiologicalcomparisonof64cuteta1a3with64cubat2it1a3‏ ‎‡A Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3.‏ ‎‡9 1‏
919 ‎‡a componentsofacurriculumformolecularimagingscientists‏ ‎‡A Components of a curriculum for molecular imaging scientists‏ ‎‡9 1‏
919 ‎‡a comparisonof4bifunctionalchelatesforradiolabelingmonoclonalantibodieswithcopperradioisotopesbiodistributionandmetabolism‏ ‎‡A Comparison of Four Bifunctional Chelates for Radiolabeling Monoclonal Antibodies with Copper Radioisotopes: Biodistribution and Metabolism‏ ‎‡9 1‏
919 ‎‡a comparisonof464culabeledsomatostatinanaloguesinvitroandinatumorbearingratmodelevaluationofnewderivativesforpositronemissiontomographyimagingandtargetedradiotherapy‏ ‎‡A Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.‏ ‎‡9 1‏
919 ‎‡a comparisonofconjugationstrategiesofcrossbridgedmacrocyclicchelatorswithcetuximabforcopper64radiolabelingandpetimagingofegfrincolorectaltumorbearingmice‏ ‎‡A Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice‏ ‎‡9 1‏
919 ‎‡a comparativestudiesofcu64atsmand10011acetateinanacutemyocardialinfarctionmodelexvivoimagingofhypoxiainrats‏ ‎‡A Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats‏ ‎‡9 1‏
919 ‎‡a comparativeinvivostabilityofcopper64labeledcrossbridgedandconventionaltetraazamacrocycliccomplexes‏ ‎‡A Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.‏ ‎‡9 1‏
919 ‎‡a comparativedosimetryofcopper64andyttrium90labeledsomatostatinanalogsinatumorbearingratmodel‏ ‎‡A Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model‏ ‎‡9 1‏
919 ‎‡a chiraldotachelatorsasanimprovedplatformforbiomedicalimagingandtherapyapplications‏ ‎‡A Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications.‏ ‎‡9 1‏
919 ‎‡a chelatorsforcopperradionuclidesinpositronemissiontomographyradiopharmaceuticals‏ ‎‡A Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals‏ ‎‡9 1‏
919 ‎‡a characterizationofsomatostatinreceptorsubtype2expressioninstablytransfecteda427humancancercells‏ ‎‡A Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells.‏ ‎‡9 1‏
919 ‎‡a characterizationandevaluationof64culabeleda20fmdv2conjugatesforimagingtheintegrinαvβ6‏ ‎‡A Characterization and evaluation of (64)Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ 6‏ ‎‡9 1‏
919 ‎‡a characterizationandevaluationof‏ ‎‡A Characterization and evaluation of‏ ‎‡9 1‏
919 ‎‡a biodegradabledendriticpositronemittingnanoprobesforthenoninvasiveimagingofangiogenesis‏ ‎‡A Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis‏ ‎‡9 1‏
919 ‎‡a agonistantagonistdilemmainmolecularimagingevaluationofamonomolecularmultimodalimagingagentforthesomatostatinreceptor‏ ‎‡A Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor‏ ‎‡9 1‏
919 ‎‡a newphosphonatependantarmedcrossbridgedtetraaminechelatoracceleratescopper2bindingforradiopharmaceuticalapplications‏ ‎‡A A new phosphonate pendant-armed cross-bridged tetraamine chelator accelerates copper(ii) binding for radiopharmaceutical applications‏ ‎‡9 1‏
919 ‎‡a 64culabeledsomatostatinanaloguesconjugatedwithcrossbridgedphosphonatebasedchelatorsviastrainpromotedclickchemistryforpetimaginginsilicothroughinvivostudies‏ ‎‡A 64Cu-labeled somatostatin analogues conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studies‏ ‎‡9 1‏
919 ‎‡a 64culabeledinhibitorsofprostatespecificmembraneantigenforpetimagingofprostatecancer‏ ‎‡A ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer‏ ‎‡9 1‏
919 ‎‡a 64culabeledcbte2aanddiamsarconjugatedrgdpeptideanalogsfortargetingangiogenesiscomparisonoftheirbiologicalactivity‏ ‎‡A (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity‏ ‎‡9 1‏
919 ‎‡a 177lulabeledphosphoramidatebasedpsmainhibitorstheeffectofanalbuminbinderonbiodistributionandtherapeuticefficacyinprostatetumorbearingmice‏ ‎‡A 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.‏ ‎‡9 1‏
919 ‎‡a 111inllp2adotapolyethyleneglycoltargetingalpha4beta1integrincomparativepharmacokineticsforimagingandtherapyoflymphoidmalignancies‏ ‎‡A 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.‏ ‎‡9 1‏
919 ‎‡a toxicityanddosimetryof177ludotay3octreotateinaratmodel‏ ‎‡A Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.‏ ‎‡9 1‏
919 ‎‡a toxicityanddosimetryof‏ ‎‡A Toxicity and dosimetry of‏ ‎‡9 1‏
919 ‎‡a theranosticnanoemulsionsformacrophagecox2inhibitioninamurineinflammationmodel‏ ‎‡A Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model.‏ ‎‡9 1‏
919 ‎‡a roleofp53inthetraffickingofcopper64totumorcellnuclei‏ ‎‡A The role of p53 in the trafficking of copper-64 to tumor cell nuclei.‏ ‎‡9 1‏
943 ‎‡a 140x‏ ‎‡A 1403‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 SUDOC|120160110‏
996 ‎‡2 LC|nr2001051358‏
996 ‎‡2 ISNI|0000000024317388‏
996 ‎‡2 NKC|jn20001227675‏
996 ‎‡2 NTA|331657538‏
996 ‎‡2 LC|n 97800004‏
996 ‎‡2 J9U|987007342741805171‏
996 ‎‡2 ISNI|0000000025451140‏
996 ‎‡2 DBC|87097948296548‏
996 ‎‡2 LC|n 94048878‏
996 ‎‡2 J9U|987007371642305171‏
996 ‎‡2 DNB|129179140‏
996 ‎‡2 BIBSYS|99051366‏
996 ‎‡2 ISNI|0000000119385658‏
996 ‎‡2 J9U|987007324761505171‏
996 ‎‡2 LC|no2019017456‏
996 ‎‡2 LC|no2024019573‏
996 ‎‡2 BNF|12444400‏
996 ‎‡2 LC|no2019030646‏
996 ‎‡2 ISNI|0000000031956372‏
996 ‎‡2 ISNI|0000000054063665‏
996 ‎‡2 CAOONL|ncf10341686‏
996 ‎‡2 J9U|987007411935905171‏
996 ‎‡2 CAOONL|ncf11354241‏
996 ‎‡2 DNB|1205825738‏
996 ‎‡2 BNF|13562301‏
996 ‎‡2 DNB|1011425149‏
996 ‎‡2 ISNI|0000000427200950‏
996 ‎‡2 BIBSYS|6015819‏
996 ‎‡2 ISNI|0000000388991963‏
996 ‎‡2 LNL|10403‏
996 ‎‡2 SELIBR|sbrvvkt2qhhvq1mx‏
996 ‎‡2 LC|n 2007069024‏
996 ‎‡2 LC|no2009013571‏
996 ‎‡2 BIBSYS|4073556‏
996 ‎‡2 J9U|987007451948505171‏
996 ‎‡2 NTA|071973265‏
996 ‎‡2 LC|n 00025298‏
996 ‎‡2 SUDOC|074767550‏
996 ‎‡2 NII|DA0084068X‏
996 ‎‡2 NTA|315157992‏
996 ‎‡2 RERO|A002928080‏
996 ‎‡2 LC|n 84039584‏
996 ‎‡2 RERO|A006363855‏
996 ‎‡2 SUDOC|165578580‏
996 ‎‡2 LC|n 85810104‏
996 ‎‡2 SUDOC|087279568‏
996 ‎‡2 SUDOC|160276810‏
996 ‎‡2 PLWABN|9810582566405606‏
996 ‎‡2 ISNI|0000000060586585‏
996 ‎‡2 BNF|12289158‏
996 ‎‡2 LC|n 83234139‏
996 ‎‡2 LC|no2016108402‏
996 ‎‡2 CAOONL|ncf11362841‏
996 ‎‡2 LC|ns2013003856‏
996 ‎‡2 SUDOC|033592209‏
996 ‎‡2 NTA|152939903‏
996 ‎‡2 LC|no2002040625‏
996 ‎‡2 BNC|981061086775706706‏
996 ‎‡2 LC|n 2007064807‏
996 ‎‡2 BIBSYS|4032584‏
996 ‎‡2 LC|nr 99025896‏
996 ‎‡2 ISNI|0000000034153903‏
996 ‎‡2 J9U|987007277323905171‏
996 ‎‡2 LC|n 83183935‏
996 ‎‡2 B2Q|0001148129‏
996 ‎‡2 NII|DA19789078‏
996 ‎‡2 RERO|A011252476‏
996 ‎‡2 LC|n 88087532‏
996 ‎‡2 LC|n 84002326‏
996 ‎‡2 LC|n 85809967‏
996 ‎‡2 BIBSYS|90273206‏
996 ‎‡2 LC|n 82033405‏
996 ‎‡2 ISNI|0000000084387476‏
996 ‎‡2 NSK|000525931‏
996 ‎‡2 RERO|A009461555‏
996 ‎‡2 PTBNP|193907‏
996 ‎‡2 LC|n 85342297‏
996 ‎‡2 SUDOC|035102640‏
996 ‎‡2 NDL|001100618‏
996 ‎‡2 ISNI|0000000045839054‏
996 ‎‡2 RERO|A012853820‏
996 ‎‡2 RERO|A016779952‏
996 ‎‡2 ISNI|0000000082572416‏
996 ‎‡2 NKC|mub2017956043‏
996 ‎‡2 NUKAT|n 2005121542‏
996 ‎‡2 LC|n 86802084‏
996 ‎‡2 RERO|A006217295‏
996 ‎‡2 BNCHL|10000000000000000798825‏
996 ‎‡2 ISNI|0000000086328998‏
996 ‎‡2 SUDOC|161080820‏
996 ‎‡2 LC|n 2009032980‏
996 ‎‡2 DNB|127582525‏
996 ‎‡2 B2Q|0000475042‏
996 ‎‡2 ISNI|0000000394726373‏
996 ‎‡2 NSK|000054825‏
996 ‎‡2 LC|n 85090076‏
996 ‎‡2 BIBSYS|4084807‏
996 ‎‡2 LC|no2001053905‏
996 ‎‡2 J9U|987007444265805171‏
996 ‎‡2 NTA|182164217‏
996 ‎‡2 ISNI|0000000074958589‏
996 ‎‡2 ISNI|0000000067476979‏
996 ‎‡2 ISNI|0000000053190830‏
996 ‎‡2 LC|n 2015014120‏
996 ‎‡2 ISNI|000000011308116X‏
996 ‎‡2 LC|n 2014021628‏
996 ‎‡2 BNF|15557498‏
996 ‎‡2 ISNI|0000000369102008‏
996 ‎‡2 NUKAT|n 2012110944‏
996 ‎‡2 NII|DA04281003‏
996 ‎‡2 ISNI|0000000029472838‏
996 ‎‡2 LC|no2021028161‏
996 ‎‡2 NUKAT|n 2018263242‏
996 ‎‡2 CAOONL|ncf10990848‏
996 ‎‡2 ISNI|0000000497587548‏
996 ‎‡2 PLWABN|9810699415905606‏
996 ‎‡2 NUKAT|n 2017050976‏
996 ‎‡2 RERO|A002928072‏
996 ‎‡2 ISNI|0000000108141981‏
996 ‎‡2 J9U|987007447101905171‏
996 ‎‡2 ISNI|0000000500029003‏
996 ‎‡2 J9U|987007446048105171‏
996 ‎‡2 NDL|001169350‏
996 ‎‡2 PTBNP|245284‏
996 ‎‡2 LC|n 98035150‏
996 ‎‡2 CAOONL|ncf10346271‏
996 ‎‡2 BNE|XX5769212‏
996 ‎‡2 LC|no2020063281‏
996 ‎‡2 NTA|071286497‏
996 ‎‡2 DNB|1179960998‏
996 ‎‡2 N6I|vtls002127023‏
996 ‎‡2 LC|no2014140455‏
996 ‎‡2 ISNI|0000000036271049‏
996 ‎‡2 ISNI|0000000052848696‏
996 ‎‡2 LC|n 95044136‏
996 ‎‡2 NUKAT|n 2010104115‏
996 ‎‡2 NII|DA14207914‏
996 ‎‡2 ISNI|0000000039721658‏
996 ‎‡2 NLA|000035389564‏
996 ‎‡2 LC|no 98034117‏
996 ‎‡2 LC|n 99262706‏
996 ‎‡2 ISNI|0000000066387210‏
996 ‎‡2 CAOONL|ncf10786919‏
996 ‎‡2 NUKAT|n 94209363‏
996 ‎‡2 NII|DA02855644‏
996 ‎‡2 ISNI|0000000082080198‏
996 ‎‡2 BNE|XX1417304‏
996 ‎‡2 B2Q|0000679239‏
996 ‎‡2 NTA|182171310‏
996 ‎‡2 ISNI|000000044921451X‏
996 ‎‡2 ISNI|000000007072278X‏
996 ‎‡2 BIBSYS|90190033‏
996 ‎‡2 BIBSYS|90915903‏
996 ‎‡2 BNF|13167153‏
996 ‎‡2 LC|nb2013022999‏
996 ‎‡2 DNB|105257081X‏
996 ‎‡2 ICCU|CUBV052055‏
996 ‎‡2 BIBSYS|90677877‏
996 ‎‡2 BNF|14523093‏
996 ‎‡2 ISNI|0000000446322486‏
996 ‎‡2 LNB|LNC10-000062835‏
996 ‎‡2 LC|n 79086200‏
996 ‎‡2 CAOONL|ncf10379772‏
996 ‎‡2 LC|no2010139308‏
996 ‎‡2 NTA|19278921X‏
996 ‎‡2 BIBSYS|90346016‏
996 ‎‡2 J9U|987007442426205171‏
996 ‎‡2 LC|no2014117809‏
996 ‎‡2 ISNI|0000000498337997‏
996 ‎‡2 J9U|987007274000205171‏
996 ‎‡2 LC|nb 97031606‏
996 ‎‡2 BNF|14483263‏
996 ‎‡2 LC|n 91021444‏
996 ‎‡2 CAOONL|ncf10504753‏
996 ‎‡2 ISNI|0000000073425924‏
996 ‎‡2 NUKAT|n 2017057272‏
996 ‎‡2 BIBSYS|4003170‏
996 ‎‡2 ISNI|0000000376501429‏
996 ‎‡2 CAOONL|ncf11166385‏
996 ‎‡2 ISNI|0000000108157721‏
996 ‎‡2 BIBSYS|90506731‏
996 ‎‡2 LC|n 2011056226‏
996 ‎‡2 ISNI|0000000118279490‏
996 ‎‡2 NUKAT|n 2003043571‏
996 ‎‡2 ISNI|0000000139415594‏
996 ‎‡2 LC|no2008182286‏
996 ‎‡2 J9U|987007447505505171‏
996 ‎‡2 CAOONL|ncf10264449‏
996 ‎‡2 NTA|085035432‏
996 ‎‡2 LC|n 91077762‏
996 ‎‡2 NUKAT|n 2012147881‏
996 ‎‡2 CAOONL|ncf10596157‏
996 ‎‡2 LC|no2016003232‏
996 ‎‡2 LIH|LNB:V-128955;=BQ‏
996 ‎‡2 ISNI|0000000034856940‏
996 ‎‡2 DNB|1338226290‏
996 ‎‡2 ISNI|0000000035377802‏
996 ‎‡2 LC|nb2007014943‏
996 ‎‡2 J9U|987007388576505171‏
996 ‎‡2 LC|no2009197647‏
996 ‎‡2 ISNI|0000000451662362‏
996 ‎‡2 BNE|XX975530‏
996 ‎‡2 ISNI|0000000075238161‏
996 ‎‡2 SUDOC|169978001‏
996 ‎‡2 LC|n 2006026982‏
996 ‎‡2 DNB|127345256‏
996 ‎‡2 LC|n 90603848‏
996 ‎‡2 NDL|00462286‏
996 ‎‡2 CAOONL|ncf11553700‏
996 ‎‡2 ISNI|0000000082792486‏
996 ‎‡2 CAOONL|ncf10649790‏
996 ‎‡2 PLWABN|9810559119705606‏
996 ‎‡2 CAOONL|ncf11403035‏
996 ‎‡2 ISNI|0000000367546078‏
996 ‎‡2 RERO|A020352789‏
996 ‎‡2 ISNI|0000000031943117‏
996 ‎‡2 PLWABN|9810568060705606‏
996 ‎‡2 LC|no2017068806‏
996 ‎‡2 SUDOC|071623523‏
996 ‎‡2 NDL|00796078‏
996 ‎‡2 LC|n 90718233‏
996 ‎‡2 SUDOC|132798549‏
996 ‎‡2 DBC|87097968066328‏
996 ‎‡2 BIBSYS|90505136‏
996 ‎‡2 NLA|000035239900‏
996 ‎‡2 LC|n 78029339‏
996 ‎‡2 BIBSYS|90662549‏
996 ‎‡2 LC|nb2019021992‏
996 ‎‡2 LC|n 87841708‏
996 ‎‡2 SUDOC|031730396‏
996 ‎‡2 RERO|A002928071‏
996 ‎‡2 J9U|987007440043605171‏
996 ‎‡2 LC|nr 91003173‏
996 ‎‡2 BIBSYS|90069621‏
996 ‎‡2 LC|n 94093087‏
996 ‎‡2 BIBSYS|90942338‏
996 ‎‡2 NTA|370969715‏
996 ‎‡2 LC|no2022071601‏
996 ‎‡2 CAOONL|ncf10786918‏
996 ‎‡2 RERO|A002928078‏
996 ‎‡2 LC|n 85372265‏
996 ‎‡2 BLBNB|000396388‏
996 ‎‡2 BIBSYS|90634278‏
996 ‎‡2 LC|n 2012015781‏
996 ‎‡2 NLA|000035580558‏
996 ‎‡2 CAOONL|ncf10284835‏
996 ‎‡2 LC|n 2001014107‏
996 ‎‡2 ISNI|0000000023617928‏
996 ‎‡2 DNB|1145711693‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏